title: Glucose inhibits phenobarbital-induced delta-aminolevulinate synthase expression in normal but not in diabetic rat hepatocytes.
abstract: In the present work, we demonstrate the presence of a glucose inhibitory effect on the phenobarbital-mediated induction of the delta-aminolevulinate synthase mRNA in normal rat hepatocytes, consistent with the results obtained with the delta-aminolevulinate synthase activity previously reported. This "glucose effect" can be prevented by adding cAMP, adenylate cyclase activators, or a phosphodiesterase inhibitor. Delta-Aminolevulinate synthase mRNA half-life is not modified in the presence of phenobarbital or glucose. When the same experiments are performed using diabetic cells, no glucose effect is observed, even when the endogenous cAMP content is lowered to normal levels. The results obtained in this study suggest that glucose decreases delta-aminolevulinate synthase biosynthesis by acting at a pretranslational step. Assuming that the glucose effect operates by a repression mechanism exerted by metabolites derived from or related to glucose, the present results may reflect a derangement in the formation of these metabolites as a result of the abnormal metabolism operating in the diabetic state.
authors.affiliation: Departamento de Quimica Biologica, Universidad de Buenos Aires, Argentina.
authors.forename: C L
authors.initials: CL
authors.lastname: Varone
authors.forename: E T
authors.initials: ET
authors.lastname: Canepa
authors.forename: E B
authors.initials: EB
authors.lastname: Llambias
authors.forename: M
authors.initials: M
authors.lastname: Grinstein
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000624:5-Aminolevulinate Synthetase / Q000096:biosynthesis* / Q000235:genetics; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000502:physiology; D003994:Bucladesine / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000201:enzymology*; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology*; D006418:Heme / Q000096:biosynthesis; D007113:Immunity, Innate; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D010634:Phenobarbital / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000633:toxicity*; D011164:Porphyrias / Q000139:chemically induced* / Q000209:etiology; D051381:Rats; D015290:Second Messenger Systems / Q000502:physiology; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D004791:Enzyme Inhibitors; D006418:Heme; D013311:Streptozocin; D003994:Bucladesine; D000242:Cyclic AMP; D000624:5-Aminolevulinate Synthetase; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000262:Adenylyl Cyclases; D005947:Glucose; D015056:1-Methyl-3-isobutylxanthine; D010634:Phenobarbital